$KRYS

Krystal Biotech (KRYS) presented at the Cantor Fitzgerald Global Healthcare Conference, highlighting its genetic medicines platform. The company reported three years of positive EPS, with VYJUVEK sales plateauing at $85M-$95M quarterly. International expansion is expected to drive growth, despite pricing pressures. Key pipeline updates include Hailey-Hailey disease, ocular programs, and a pulmonary cancer program. Shares closed at $345.55, down 0.73%.

Enovis Corp. (ENOV) insiders bought shares near a 52-week low, with CEO Damien McDonald acquiring 13,035 shares at $19.10-$19.16. Atara Biotherapeutics (ATRA) director bought 104,166 shares at $9.60. Smith-Midland Corp. (SMID) insiders also made purchases. Illumina (ILMN) director sold $57.2M in shares near a 52-week high. Caris Life Sciences (CRIS) exec sold $14.8M in shares. Okta (OKTA) CFO sold 80,000 shares. Krystal Biotech (KRY) execs sold shares near a 52-week high.

Krishnan Suma (President, R&D) sold 25,000 shares of Krystal Biotech, Inc. (KRYS) at an average of $359.32 ($354.54–$366.56, $8.98M total) across 13 trades on 2026-09-04 under a Rule 10b5-1 trading plan.

Krishnan Krish S (President and CEO) sold 25,000 shares of Krystal Biotech, Inc. (KRYS) at an average of $359.32 ($354.54–$366.56, $8.98M total) across 13 trades on 2026-09-04 under a Rule 10b5-1 trading plan.

Krystal Biotech (KRYS) shares rose 12% since its last earnings report, outperforming the S&P 500. The company reported Q2 2026 EPS of $1.79, beating estimates, with revenues of $119.2M, up 24% YoY. Vyjuvek sales drove growth, and the company maintained its 2026 guidance. Analysts have upwardly revised estimates, but the stock's momentum and value scores are low.

Investing.com reported major US insider trades disclosed Friday. Buys: PAL director Rohit Lal bought $272.5k; OTLK director/10% owner Ghiath Sukhtian bought about 2.5M shares and warrants for ~$2.5M; CLPR director Sam Levinson bought ~$488.8k; OPFI CEO Todd Schwartz bought ~$144k; OPEN CEO Kasra Nejatian bought ~$100k. Sells: CRWV 10% owner Magnetar sold ~$231.6M then ~$213.8M; ANET CEO Ullal trust sales ~$119.3M; SEPN RA Capital sold $63.45M; KRYS director Rossi sold ~$8.23M.

Krystal Biotech director Dino A. Rossi sold about 25,000 shares for roughly $8.23m on Aug. 14, 2026, per an SEC Form 4, at weighted average prices of $325.60 to $333.23. He also gifted 3,691 shares to a donor-advised fund. Krystal Biotech reported Q2 diluted EPS of $1.79 (vs $1.70 est.) and revenue of $119.2m (vs $122.3m est.).

ROSSI DINO A sold 25,000 shares of Krystal Biotech, Inc. (KRYS) at an average of $329.12 ($325.60–$333.23, $8.23M total) across 8 trades on 2026-08-14.

Analyst notes on Friday included KeyBanc reiterating Apple as underweight, citing iPhone 17 carrier survey data slightly positive but with iPhone 18 price uncertainty. Bernstein upgraded Wayfair to Outperform, raising its PT to $125. Morgan Stanley reiterated Nvidia as overweight. Other calls covered Fox, Intuitive Machines, Cinemark, SanDisk, Energy Fuels, Digital Realty, SpaceX, Dell, Micron, and T-Mobile.

The article reports Friday’s Wall Street analyst research calls after cooler-than-expected CPI and PPI helped lift the S&P 500 to a record and Nasdaq up 0.81%. It cites upgrades, downgrades, and initiations including JPMorgan upgrading FoxA to Overweight with an $82 target and RBC initiating Krystal Biotech (KRYS) at $400. It also lists multiple other price targets across stocks.